Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Vitamin B2 (Riboflavin): Increases metabolic rate and supports immune function
Research has also examined the compounds stability and formulation requirements
Some mild and short-lived side effects can include: Mild soreness or redness at the injection site A feeling of warmth after the injection A short-lived mild headache Feeling slightly flushed Serious reactions are very rare
